Marcia A. Rench

TL;DR: It is concluded that maternal immunization is feasible and can provide passive immunity against systemic infection with Type III group B streptococcus in the majority of newborns.

TL;DR: Pertussis antibodies in maternal-infant paired sera from 1999-2000 support the rationale for maternal or neonatal immunization, with acellular pertussis vaccines, to prevent life-threatening pertussi in early infancy.

TL;DR: In this setting, a complete series of RV5 was highly effective against severe rotavirus AGE and partial immunization also conferred substantial protection.

TL;DR: From 1993 through 1996, surveillance for invasive disease in neonates aged <7 days and in peripartum pregnant women was performed in a racially and ethnically diverse cohort in 4 cities in the United States, providing a description of invasive GBS perinatal infection during the period in which guidelines for prevention were actively disseminated.

TL;DR: Changes in the epidemiology of GBS colonization included diminished rates in some populations associated with use of maternal intrapartum antibiotics, and a shift in serotype prevalence, with Ia as predominant and V, in addition to II and III, as common.